Tags

Type your tag names separated by a space and hit enter

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
J Clin Psychiatry. 2004 Mar; 65(3):312-21.JC

Abstract

BACKGROUND

The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study was designed to provide information regarding use and outcome of antipsychotic treatments in a large, diverse population in real practice settings.

METHOD

Outpatients with schizophrenia (ICD-10 or DSM-IV) who initiated or changed to a new antipsychotic entered this 3-year, naturalistic, prospective observational study. Four monotherapy treatment groups were defined according to the antipsychotic prescribed at baseline, namely olanzapine, risperidone, quetiapine, and haloperidol. Efficacy was assessed using the Clinical Global Impressions-Severity of Illness rating scale (CGI-S), inclusive of subscales for positive, negative, depressive, and cognitive symptoms. Tolerability was assessed by adverse event questionnaires and weight measurements. Six-month findings are described.

RESULTS

At baseline, 5833 participants were prescribed monotherapy and the mean severity of illness was moderate to marked (CGI-S). At 6 months, olanzapine resulted in significantly greater improvements in overall, positive, negative, depressive, and cognitive symptoms compared with quetiapine, risperidone or haloperidol (p <.001). Improvements in overall, negative, and cognitive symptoms were significantly higher for risperidone compared with haloperidol (p <.001), whereas improvements across all symptoms were comparable for quetiapine and haloperidol. Extra-pyramidal symptoms and tardive dyskinesia decreased compared with baseline in the olanzapine, quetiapine, and risperidone groups but increased in the haloperidol group (p <.001, likelihood of extrapyramidal symptoms with haloperidol compared with olanzapine, quetiapine, or risperidone). Sexual function adverse events were most prominent in the haloperidol and risperidone treatment groups. Weight change was significantly greater for olanzapine compared with the other antipsychotics (p <.001).

CONCLUSION

Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia.

Authors+Show Affiliations

Eli Lilly Ges.m.b.H., Barichgasse 40-52, Vienna 1030, Austria. d.m.@lilly.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15096069

Citation

Dossenbach, Martin, et al. "Effectiveness of Antipsychotic Treatments for Schizophrenia: Interim 6-month Analysis From a Prospective Observational Study (IC-SOHO) Comparing Olanzapine, Quetiapine, Risperidone, and Haloperidol." The Journal of Clinical Psychiatry, vol. 65, no. 3, 2004, pp. 312-21.
Dossenbach M, Erol A, el Mahfoud Kessaci M, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004;65(3):312-21.
Dossenbach, M., Erol, A., el Mahfoud Kessaci, M., Shaheen, M. O., Sunbol, M. M., Boland, J., Hodge, A., O'Halloran, R. A., & Bitter, I. (2004). Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. The Journal of Clinical Psychiatry, 65(3), 312-21.
Dossenbach M, et al. Effectiveness of Antipsychotic Treatments for Schizophrenia: Interim 6-month Analysis From a Prospective Observational Study (IC-SOHO) Comparing Olanzapine, Quetiapine, Risperidone, and Haloperidol. J Clin Psychiatry. 2004;65(3):312-21. PubMed PMID: 15096069.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. AU - Dossenbach,Martin, AU - Erol,Almila, AU - el Mahfoud Kessaci,Mohand, AU - Shaheen,Mostafa O, AU - Sunbol,Mohammed M, AU - Boland,Jason, AU - Hodge,Andrew, AU - O'Halloran,Ruth A, AU - Bitter,Istvan, AU - ,, PY - 2004/4/21/pubmed PY - 2004/5/21/medline PY - 2004/4/21/entrez SP - 312 EP - 21 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 65 IS - 3 N2 - BACKGROUND: The Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study was designed to provide information regarding use and outcome of antipsychotic treatments in a large, diverse population in real practice settings. METHOD: Outpatients with schizophrenia (ICD-10 or DSM-IV) who initiated or changed to a new antipsychotic entered this 3-year, naturalistic, prospective observational study. Four monotherapy treatment groups were defined according to the antipsychotic prescribed at baseline, namely olanzapine, risperidone, quetiapine, and haloperidol. Efficacy was assessed using the Clinical Global Impressions-Severity of Illness rating scale (CGI-S), inclusive of subscales for positive, negative, depressive, and cognitive symptoms. Tolerability was assessed by adverse event questionnaires and weight measurements. Six-month findings are described. RESULTS: At baseline, 5833 participants were prescribed monotherapy and the mean severity of illness was moderate to marked (CGI-S). At 6 months, olanzapine resulted in significantly greater improvements in overall, positive, negative, depressive, and cognitive symptoms compared with quetiapine, risperidone or haloperidol (p <.001). Improvements in overall, negative, and cognitive symptoms were significantly higher for risperidone compared with haloperidol (p <.001), whereas improvements across all symptoms were comparable for quetiapine and haloperidol. Extra-pyramidal symptoms and tardive dyskinesia decreased compared with baseline in the olanzapine, quetiapine, and risperidone groups but increased in the haloperidol group (p <.001, likelihood of extrapyramidal symptoms with haloperidol compared with olanzapine, quetiapine, or risperidone). Sexual function adverse events were most prominent in the haloperidol and risperidone treatment groups. Weight change was significantly greater for olanzapine compared with the other antipsychotics (p <.001). CONCLUSION: Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/15096069/Effectiveness_of_antipsychotic_treatments_for_schizophrenia:_interim_6_month_analysis_from_a_prospective_observational_study__IC_SOHO__comparing_olanzapine_quetiapine_risperidone_and_haloperidol_ L2 - http://www.psychiatrist.com/jcp/article/pages/2004/v65n03/v65n0305.aspx DB - PRIME DP - Unbound Medicine ER -